EQL: EQL Pharma AB (publ) - Summary | Jitta

EQL Pharma AB (publ)

SWE:EQL

Price
kr25.75
Loss Chance
54.2%
2.59JITTA SCORE
203.84%Over Jitta Line
Jitta Ranking
73 / 107
519 / 619
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (32)
Recent Business Performance (17)
Financial Strength (61)
Return to Shareholders (21)
Competitive Advantage (43)
Jitta Signs
Revenue and EarningEarning decline from 2023-2026
Operating MarginDeclined
Debt LevelHigh Long Term Debt
Recent Business PerformanceEarning decline 268.58% in the last quarter (yoy)
SG&A to SalesIncreasing
Key Stats
Jitta Score
Jitta Line
2.59
203.84%
2.90
164.20%
Health Care Distributors
5.35
39.23%
COMPANY DESCRIPTION
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers prescription drugs, including hospital products. EQL Pharma AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.